research Combined C3b and Factor B Autoantibodies and MPGN Type II
The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
Search
for
Sort by
Research
840-870 / 1000+ results
research Anti-androgenic therapy with finasteride in patients with chronic heart failure – a retrospective propensity score based analysis
Finasteride helps reduce heart enlargement in heart failure patients.
research Assessment of the Pharmacokinetic -Pharmacodynamic Interaction Between Terazosin and Finasteride
Terazosin and finasteride together cause no major issues.
research Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?
5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
research Prescribers alerted to potential adverse effects of finasteride and montelukast
research Hair loss with antidepressants
Some antidepressants can cause rare hair loss, which can significantly affect patients' well-being.
research Bisphenol-A antagonizes the rapidly modulating effect of DHT on spinogenesis and long-term potentiation of hippocampal neurons
Bisphenol-A (BPA) increases connections between brain cells and boosts their activity, but it blocks the effects of a male hormone on brain cell plasticity.
research Effectiveness and safety of physician–pharmacist collaborative care for rheumatoid arthritis patients: The Changi General Hospital’s experience
Collaborative care between physicians and pharmacists improved medication management for rheumatoid arthritis without raising costs.
research The scope and use of valproate in epilepsy.
Valproate is effective for epilepsy but has side effects and requires careful monitoring.
research Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
Dutasteride 0.5 mg daily improves hair growth safely in men with hair loss.
research The Effect of 5 -Reductase Inhibitors on Erectile Function
5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?
Drugs like PDEI may help hair disorders like AGA.
research A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia
research Differential association between cumulative dose of 5α-reductase inhibitors and mortality
Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
research Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
PRP injections are safe but don't significantly improve Peyronie's Disease.
research Associations between semen quality and lower urinary tract symptoms in ageing male
The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
research Finasteride-related suicidal ideation reported to Lareb
research Efficacy of different doses of platelet-rich plasma for moderate carpal tunnel syndrome: study protocol for a prospective, randomized, controlled trial in Guangzhou, China
The study aims to find the best platelet-rich plasma dose to relieve moderate carpal tunnel syndrome symptoms.
research Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults
Certain groups of medications given when leaving the hospital are linked to a higher risk of negative drug reactions within 30 days, especially in older adults with respiratory issues.
research P-215 Study on Bioequivalence of Finasteride Tablet in Healthy Volunteers
research Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
research Effect of ethanol Adiantum capillus-veneris extract in experimental models of anxiety and depression
Maidenhair fern extract reduced anxiety and depression in rats and may work due to its antioxidant and anti-inflammatory properties.
research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation
Dutasteride-containing mesotherapy effectively treats female hair loss, improving density and thickness with minimal side effects.
research Novel drugs of United States Food and Drug Administration approved in 2024
In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
research A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia
Dutasteride 0.5 mg works better than finasteride and placebo for increasing hair in men with hair loss.
research Implicações da toma crónica da Finasteride para a Alopécia Androgenética no Carcinoma da Próstata
Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.